Literature DB >> 12414638

Increased exposure of anionic phospholipids on the surface of tumor blood vessels.

Sophia Ran1, Amber Downes, Philip E Thorpe.   

Abstract

Anionic phospholipids are largely absent from the external leaflet of the plasma membrane of mammalian cells under normal conditions. Exposure of phosphatidylserine on the cell surface occurs during apoptosis, necrosis, cell injury, cell activation, and malignant transformation. In the present study, we determined whether anionic phospholipids become exposed on tumor vasculature. A monoclonal antibody, 9D2, which specifically recognizes anionic phospholipids, was injected into mice bearing a variety of orthotopic or ectopic tumors. Other mice received annexin V, a natural ligand that binds to anionic phospholipids. Both 9D2 and annexin V specifically localized to vascular endothelium in all of the tumors, and also to tumor cells in and around regions of necrosis. Between 15 and 40% of endothelial cells in tumor vessels were stained. No localization was detected on normal endothelium. Various factors and tumor-associated conditions known to be present in the tumor microenvironment were examined for their ability to cause exposure of anionic phospholipids in cultured endothelial cells, as judged by 9D2 and annexin V binding. Hypoxia/reoxygenation, acidity, thrombin, and inflammatory cytokines all induced exposure of anionic phospholipids. Hydrogen peroxide was also a strong inducer. Combined treatment with inflammatory cytokines and hypoxia/reoxygenation had greater than additive effects. Possibly, injury and activation of tumor endothelium by cytokines and reactive oxygen species induce exposure of anionic phospholipids, most likely phosphatidylserine. Anionic phospholipids on tumor vessels could potentially provide markers for tumor vessel targeting and imaging.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12414638

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  137 in total

Review 1.  Tumor cell membrane-targeting cationic antimicrobial peptides: novel insights into mechanisms of action and therapeutic prospects.

Authors:  Amy A Baxter; Fung T Lay; Ivan K H Poon; Marc Kvansakul; Mark D Hulett
Journal:  Cell Mol Life Sci       Date:  2017-08-02       Impact factor: 9.261

Review 2.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

3.  Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.

Authors:  Yayun Liang; Cynthia Besch-Williford; Indira Benakanakere; Philip E Thorpe; Salman M Hyder
Journal:  Breast Cancer Res Treat       Date:  2010-03-27       Impact factor: 4.872

4.  Trial Watch: Monoclonal antibodies in cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Jessica Zucman-Rossi; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

5.  Cancer-suppressive effect of RNase A and DNase I.

Authors:  O A Shklyaeva; N L Mironova; E M Malkova; O S Taranov; E I Ryabchikova; M A Zenkova; V V Vlasov
Journal:  Dokl Biochem Biophys       Date:  2008 May-Jun       Impact factor: 0.788

6.  Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial.

Authors:  Ali A Mokdad; Hao Zhu; Muhammad S Beg; Yull Arriaga; Jonathan E Dowell; Amit G Singal; Adam C Yopp
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

7.  Vessel-Targeted Chemophototherapy with Cationic Porphyrin-Phospholipid Liposomes.

Authors:  Dandan Luo; Jumin Geng; Nasi Li; Kevin A Carter; Shuai Shao; G Ekin Atilla-Gokcumen; Jonathan F Lovell
Journal:  Mol Cancer Ther       Date:  2017-07-20       Impact factor: 6.261

8.  Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells.

Authors:  Jamie S Mader; Daniel Smyth; Jean Marshall; David W Hoskin
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

9.  Optical imaging of mammary and prostate tumors in living animals using a synthetic near infrared zinc(II)-dipicolylamine probe for anionic cell surfaces.

Authors:  Bryan A Smith; Walter J Akers; W Matthew Leevy; Andrew J Lampkins; Shuzhang Xiao; William Wolter; Mark A Suckow; Samuel Achilefu; Bradley D Smith
Journal:  J Am Chem Soc       Date:  2010-01-13       Impact factor: 15.419

10.  Ubiquitous yet distinct expression of podocalyxin on vascular surfaces in normal and tumor tissues in the rat.

Authors:  Jacqueline E Testa; Adrian Chrastina; Yan Li; Phil Oh; Jan E Schnitzer
Journal:  J Vasc Res       Date:  2009-01-10       Impact factor: 1.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.